Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

B cell receptors (BCRs) and T cell receptors (TCRs) make up an essential network of defense molecules that, collectively, can distinguish self from non-self and facilitate destruction of antigen-bearing cells such as pathogens or tumors. The analysis of BCR and TCR repertoires plays an important role in both basic immunology as well as in biotechnology. Because the repertoires are highly diverse, specialized software methods are needed to extract meaningful information from BCR and TCR sequence data. Here, we review recent developments in bioinformatics tools for analysis of BCR and TCR repertoires, with an emphasis on those that incorporate structural features. After describing the recent sequencing technologies for immune receptor repertoires, we survey structural modeling methods for BCR and TCRs, along with methods for clustering such models. We review downstream analyses, including BCR and TCR epitope prediction, antibody-antigen docking and TCR-peptide-MHC Modeling. We also briefly discuss molecular dynamics in this context.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366105PMC
http://dx.doi.org/10.1016/j.csbj.2020.07.008DOI Listing

Publication Analysis

Top Keywords

bcr tcr
16
receptor repertoires
8
cell receptors
8
analysis bcr
8
tcr repertoires
8
repertoires
5
bcr
5
methods
4
methods sequence
4
sequence structural
4

Similar Publications

Autoimmune diseases (AIDs) constitute a group of disorders where the immune system mistakenly attacks the body's tissues. The pathogenesis of AIDs involve a breakdown in immune tolerance, culminating in an immune response that targets autoantigens. In adaptive immunity, secondary rearrangement of T cell receptors (TCRs) and B cell receptors (BCRs) involves sequential V(D)J recombination events during lymphocyte development.

View Article and Find Full Text PDF

MED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancer.

Funct Integr Genomics

September 2025

Department of Thoracic Surgery, Shanghai East Hospital, Tongji University, 1800 Yuntai Road, Shanghai, 200120, China.

Although immunotherapy for late-stage non-small cell lung carcinoma (NSCLC) has been clinically utilized, its prognosis remains highly heterogeneous, prompting us to investigate novel predictive immunotherapy biomarkers for NSCLC. We analyzed the correlations between MED12 nonsynonymous mutations and survival, clinical, genomic, transcriptomic information, and immune infiltration information through data mining across multiple datasets. We also investigated the mechanism of MED12 using luciferase assay, Western blot, ChIP-PCR, and siRNA.

View Article and Find Full Text PDF

Background: The immune system is of paramount importance in maintaining human health and defending against pathogens. Among them, the adaptive immune system is a crucial component of the immune system, as it is responsible for generating and modulating the immune repertoire, which is vital for immune responses.

Methods: We conducted a comprehensive analysis of T cell receptor (TCR) and B cell receptor (BCR) clonotypes in the peripheral blood immune repertoire of 20 patients with benign and malignant ovarian tumors.

View Article and Find Full Text PDF

Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results.

Nat Med

August 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.

Recent advancements in cancer immunotherapy have improved patient outcomes, yet responses to immunotherapy remain moderate. Immunosenescence has been shown to contribute to the development and progression of various diseases; however, its specific role in solid tumors has not been fully delineated. Here we conducted a phase 2 clinical trial involving 51 patients with cancer undergoing neoadjuvant chemoimmunotherapy and applied single-cell RNA as well as TCR and BCR sequencing on tumor and blood samples to elucidate the immune cell perturbations.

View Article and Find Full Text PDF

The Coronavirus disease 2019 (COVID-19) has rapidly become the worst pandemic since the 1918 influenza pandemic. Studies have shown that severe COVID-19 patients have immune dysfunction. To characterize the dysregulated immune response to SARS-CoV-2 infection, we performed a comprehensive analysis of scRNA-seq and scV(D)J-seq in peripheral blood mononuclear cells from mild, moderate, and severe patients.

View Article and Find Full Text PDF